clinical trial · NCT07447102
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
Dragonboat Biopharmaceutical Company Limited·phase2·not yet recruiting·n = 96
Idiopathic Pulmonary Fibrosis (IPF)BC006Placebo
brief summary
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
started
Apr 1, 2026
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Mar 3, 2026
official title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BC006 in Patients With Idiopathic Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol